These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36451399)

  • 1. The role of tolvaptan in pulmonary hypertension: A retrospective study.
    Chen Q; Luo H; Li Y
    Medicine (Baltimore); 2022 Nov; 101(47):e31587. PubMed ID: 36451399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery.
    Kerling A; Toka O; Rüffer A; Müller H; Habash S; Weiss C; Dittrich S; Moosmann J
    BMC Pediatr; 2019 Feb; 19(1):57. PubMed ID: 30755181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypernatremia induced by low-dose Tolvaptan in a Patient with refractory heart failure: A case report.
    Li T; Li GS
    Medicine (Baltimore); 2019 Jul; 98(27):e16229. PubMed ID: 31277136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome.
    Saimiya M; Kaku Y; Nishimura M
    CEN Case Rep; 2021 Nov; 10(4):523-526. PubMed ID: 33904139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    Hiramine Y; Uto H; Mawatari S; Kanmura S; Imamura Y; Hiwaki T; Saishoji A; Oku M; Tokushige K; Maenohara S; Ido A
    J Gastroenterol; 2021 Jan; 56(1):54-66. PubMed ID: 32959093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment of Congestive Heart Failure Due to Severe Aortic Valve Stenosis With Low Dose Tolvaptan in Elderly Patients.
    Takasu K; Miyazaki T; Negoro K; Yatsu S; Shimizu M; Murata A; Kato T; Suda S; Hiki M; Kasai T; Miyauchi K; Daida H
    Int Heart J; 2017 May; 58(3):378-384. PubMed ID: 28539565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.
    Costello-Boerrigter LC; Boerrigter G; Cataliotti A; Harty GJ; Burnett JC
    Circ Heart Fail; 2010 May; 3(3):412-9. PubMed ID: 20176717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.
    Kiuchi S; Ikeda T
    Intern Med; 2019 Feb; 58(4):471-475. PubMed ID: 30210135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.
    Komiya S; Katsumata M; Ozawa M; Haze T; Kawano R; Ohki Y; Suzuki S; Kobayashi Y; Fujiwara A; Saka S; Tamura K; Hirawa N
    Clin Exp Nephrol; 2022 Sep; 26(9):851-858. PubMed ID: 35471469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotection by long-term low-dose tolvaptan in patients with heart failure and hyponatremia.
    Oka T; Hamano T; Ohtani T; Doi Y; Shimada K; Matsumoto A; Yamaguchi S; Hashimoto N; Senda M; Sakaguchi Y; Matsui I; Nakamoto K; Sera F; Hikoso S; Sakata Y; Isaka Y
    ESC Heart Fail; 2021 Dec; 8(6):4904-4914. PubMed ID: 34554640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
    Ikeda Y; Inomata T; Kida K; Shibagaki Y; Sato N; Izumi T; Ako J;
    Heart Vessels; 2019 Mar; 34(3):442-451. PubMed ID: 30259172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tolvaptan on the short and mid-term prognosis in elderly patients with acute heart failure coexisting with oliguria: A retrospective cohort study.
    Liu Y; Zhang Y; Chen H; Zhao J; Ma Q; Yang G; Wang X; Wu Z; Hou J; Cheng Q; Ao Q
    Front Cardiovasc Med; 2022; 9():1075631. PubMed ID: 36698930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Chishina H; Hagiwara S; Nishida N; Ueshima K; Sakurai T; Ida H; Minami Y; Takita M; Kono M; Minami T; Iwanishi M; Umehara Y; Watanabe T; Komeda Y; Arizumi T; Kudo M
    Dig Dis; 2016; 34(6):659-664. PubMed ID: 27750234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan can improve clinical course in responders.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2013; 54(6):377-81. PubMed ID: 24309447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status.
    Yamamoto T; Miura SI; Shirai K; Urata H
    J Clin Med Res; 2019 Jan; 11(1):49-55. PubMed ID: 30627278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of congestive heart failure with concomitant administration of tolvaptan to enhance the effects of furosemide.
    Nishizaki Y; Yamagami S; Sesoko M; Yamashita H; Daida H
    J Cardiol Cases; 2013 Nov; 8(5):151-154. PubMed ID: 30546768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan.
    Takimura H; Hada T; Kawano M; Yabe T; Takimura Y; Nishio S; Nakano M; Tsukahara R; Muramatsu T
    PLoS One; 2018; 13(11):e0207481. PubMed ID: 30427915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tolvaptan on improvement of tricuspid regurgitation and right ventricular dimension in patients with right-sided heart failure.
    Murakami T; Nakamura N; Natsumeda M; Matsumoto S; Sakai K; Ohno Y; Nakazawa G; Shinozaki N; Ikari Y
    Heart Vessels; 2022 Jul; 37(7):1153-1161. PubMed ID: 35050407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.